Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 36, 2023 - Issue 6
69
Views
1
CrossRef citations to date
0
Altmetric
Original Research: Gastroenterology

Primary sclerosing cholangitis hospitalizations in the United States: characteristics and predictors of clinical outcomes

, MDORCID Icon, ORCID Icon, , MD, , MD, , MD, , MD & , MD show all
Pages 700-704 | Received 24 May 2023, Accepted 29 Aug 2023, Published online: 14 Sep 2023

  • Warren KW, Athanassiades S, Monge JI. Primary sclerosing cholangitis. Am J Surg. 1966;111(1):23–38. doi:10.1016/0002-9610(66)90339-4.
  • Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology. 2013;145(3):521–536. doi:10.1053/j.gastro.2013.06.052.
  • Hirschfield GM, Beuers U, Corpechot C, et al. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–172. doi:10.1016/j.jhep.2017.03.022.
  • Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125(5):1364–1369. doi:10.1016/j.gastro.2003.07.011.
  • Poropat G, Giljaca V, Stimac D, Gluud C. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2011;2011(1):CD003626. doi:10.1002/14651858.CD003626.pub2.
  • Angulo P, Batts KP, Jorgensen RA, LaRusso NA, Lindor KD. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol. 2000;95(9):2333–2337. doi:10.1111/j.1572-0241.2000.02323.x.
  • Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology. 1994;106(2):494–499. doi:10.1016/0016-5085(94)90610-6.
  • Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis—a comprehensive review. J Hepatol. 2017;67(6):1298–1323. doi:10.1016/J.JHEP.2017.07.022.
  • Office of Minority Health. Black/African American. https://minorityhealth.hhs.gov/omh/browse.aspx?lvl=3&lvlid=61. Accessed May 16, 2023.
  • Koczka CP, Geraldino-Pardilla LB, Lawlor G. Primary sclerosing cholangitis and its relationship to the colon in a black cohort of inflammatory bowel disease patients. J Clin Gastroenterol. 2014;48(2):e19–e21. doi:10.1097/mcg.0b013e31829455b5.
  • Goldberg DS, Levy C, Yimam K, et al. Primary sclerosing cholangitis is not rare among blacks in a multicenter North American consortium. Clin Gastroenterol Hepatol. 2018;16(4):591–593. doi:10.1016/j.cgh.2017.10.028.
  • Toy E, Balasubramanian S, Selmi C, Li CS, Bowlus CL. The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. BMC Gastroenterol. 2011;11:83. doi:10.1186/1471-230X-11-83.
  • Weismüller TJ, Strassburg CP, Trivedi PJ, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology. 2017;152(8):1975–1984.e8. doi:10.1053/J.GASTRO.2017.02.038.
  • Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045–2055. doi:10.1002/hep.26565.
  • Bowlus CL, Arrivé L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2022;77(2):659–702. doi:10.1002/hep.32771.
  • Altekruse SF, Petrick JL, Rolin AI, et al. Geographic variation of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and hepatocellular carcinoma in the United States. PLoS One. 2015;10(4):e0120574. doi:10.1371/journal.pone.0120574.
  • Shiosaki JR, Sempokuya T, Hernandez BY, Wong LL. Cholangiocarcinoma in Pacific Islanders compared to Asians. Hawaii J Health Soc Welf. 2021;80(4):80–87.
  • Prokopič M, Beuers U. Management of primary sclerosing cholangitis and its complications: an algorithmic approach. Hepatol Int. 2020;15(1):6–20. doi:10.1007/s12072-020-10118-x.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.